A powerful point-of-sale partnership that delivers on the promise of affordable insulin

Click here to subscribe to Fiercebiotech.com

1 year ago

Html
Text

This week's Fierce Pharma is brought to you by GoodRx.
Trouble viewing? Click here.

GoodRx + Sanofi broaden access & affordability for people with diabetes.

GoodRx announces new way for consumers to access Sanofi’s Lantus for $35 at over 70,000 pharmacies nationwide.

In October GoodRx announced it is working with Sanofi, a global leader in diabetes care, to offer a new way for people living with diabetes to access Lantus® (insulin glargine injection) 100 Units/mL in the U.S. for only $35. This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap OOP costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024.

Read the article about this unique partnership that leverages GoodRx’s reach and scale to broaden access and affordability for people living with diabetes. This means that all Americans with a valid prescription, regardless of insurance status, can use GoodRx at over 70,000 U.S. retail pharmacies to access a 30-day supply of Lantus for only $35. The price is available to cash-paying patients with a valid prescription.

Learn more about how GoodRx + Sanofi delivered on the promise of more affordable insulin.

READ THE ARTICLE

2701 Olympic Blvd - West Building - Suite 200 - Santa Monica, CA 90404
Copyright © 2011-2023 GoodRx, Inc.

Download the App

Want to reach 160,000+ Fierce Pharma subscribers with your own message?
Contact aalcover@questex.comor call 202-824-5074.

You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Pharma's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor
New York, NY 10017

Share on

Other newsletters from Fiercebiotech.com

| 11.23.24 | House passes sweeping nonprofits bill; Trump taps Dr. Oz to run CMS Fiercebiotech.com
Yesterday at 13:32
| 11.22.24 | Halozyme ends $2B pursuit of 'unwilling' Evotec; Lexicon cuts 60% of workforce Fiercebiotech.com
Yesterday at 20:32
| 11.22.24 | Rett patient dies in Neurogene trial; AZ scraps opioid disorder drug over antifungal interaction Fiercebiotech.com
Last Friday at 17:35

More newsletters from Fiercebiotech.com

A powerful point-of-sale partnership that delivers on the promise of affordable insulin

Share on

Other newsletters from Fiercebiotech.com

Related newsletters